A DRD2 and ANKK1 haplotype is associated with nicotine dependence

Psychiatry Research

Volumn 196, Issue 2-3, 2012, Pages 285-289

  Voisey, Joanne ^a   Swagell, Christopher Dean ^a   Hughes, Ian Paul ^a   van Daal, Angela ^a,b   Noble, Ernest Pascal ^c   Lawford, Bruce Robert ^a,d   Young, Ross McDonald ^a   Morris, Charles Phillip ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b BOND UNIVERSITY   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Addiction; ANKK1; Dopamine D2 receptor; Genetic association; Haplotype

Indexed keywords

ANKYRIN; CYTOSINE; DOPAMINE 2 RECEPTOR; THYMINE;

ADULT; ANKK1 GENE; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; DRD2 GENE; FEMALE; GENE; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TOBACCO DEPENDENCE;

ADULT; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, DOPAMINE D2; TOBACCO USE DISORDER; YOUNG ADULT;

EID: 84861459614     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.09.024     Document Type: Article

References (37)

1. Abramson J.H. WINPEPI (PEPI-for-Windows): computer programs for epidemiologists. Epidemiologic Perspectives and Innovations 2004, 1:6.
2. Brody A.L., Olmstead R.E., London E.D., Farahi J., Meyer J.H., Grossman P., Lee G.S., Huang J., Hahn E.L., Mandelkern M.A. Smoking-induced ventral striatum dopamine release. The American Journal of Psychiatry 2004, 161:1211-1218.
3. Cami J., Farre M. Drug addiction. The New England Journal of Medicine 2003, 349:975-986.
4. Carter K.W., McCaskie P.A., Palmer L.J. JLIN: a java based linkage disequilibrium plotter. BMC Bioinformatics 2006, 7:60.
5. Connor J.P., Young R.M., Lawford B.R., Saunders J.B., Ritchie T.L., Noble E.P. Heavy nicotine and alcohol use in alcohol dependence is associated with D2 dopamine receptor (DRD2) polymorphism. Addictive Behaviors 2007, 32:310-319.
6. Connor J.P., Young R.M., Saunders J.B., Lawford B.R., Ho R., Ritchie T.L., Noble E.P. The A1 allele of the D2 dopamine receptor gene region, alcohol expectancies and drinking refusal self-efficacy are associated with alcohol dependence severity. Psychiatry Research 2008, 160:94-105.
7. Corrigall W.A., Franklin K.B., Coen K.M., Clarke P.B. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berlin) 1992, 107:285-289.
8. Corrigall W.A., Coen K.M., Adamson K.L. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Research 1994, 653:278-284.
9. Duan J., Wainwright M.S., Comeron J.M., Saitou N., Sanders A.R., Gelernter J., Gejman P.V. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Human Molecular Genetics 2003, 12:205-216.
10. Dubertret C., Gouya L., Hanoun N., Deybach J.C., Ades J., Hamon M., Gorwood P. The 3' region of the DRD2 gene is involved in genetic susceptibility to schizophrenia. Schizophrenia Research 2004, 67:75-85.
11. Gelernter J., Liu X., Hesselbrock V., Page G.P., Goddard A., Zhang H. Results of a genomewide linkage scan: support for chromosomes 9 and 11 loci increasing risk for cigarette smoking. American Journal of Medical Genetics Part B 2004, 128B:94-101.
12. Gelernter J., Yu Y., Weiss R., Brady K., Panhuysen C., Yang B.Z., Kranzler H.R., Farrer L. Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Human Molecular Genetics 2006, 15:3498-3507.
13. Grieder T.E., Sellings L.H., Vargas-Perez H., Ting A.K.R., Siu E.C., Tyndale R.F., van der Kooy D. Dopaminergic signaling mediates the motivational response underlying the opponent process to chronic but not acute nicotine. Neuropsychopharmacology 2010, 35:943-954.
14. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction 1991, 86:1119-1127.
15. Hirvonen M., Laakso A., Nagren K., Rinne J.O., Pohjalainen T., Hietala J. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Molecular Psychiatry 2004, 9:1060-1061. Erratum 10, 889.
16. Ho M.K., Tyndale R.F. Overview of the pharmacogenomics of cigarette smoking. The Pharmacogenomics Journal 2007, 7:81-98.
17. Hurd Y.L., Suzuki M., Sedvall G.C. D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain. Journal of Chemical Neuroanatomy 2001, 22:127-137.
18. Imperato A., Mulas A., Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. European Journal of Pharmacology 1986, 132:337-338.
19. Jacobsen L.K., Pugh K.R., Mencl W.E., Gelernter J. C957T polymorphism of the dopamine D2 receptor gene modulates the effect of nicotine on working memory performance and cortical processing efficiency. Psychopharmacology (Berlin) 2006, 188:530-540.
20. Johnstone E.C., Yudkin P.L., Hey K., Roberts S.J., Welch S.J., Murphy M.F., Griffiths S.E., Walton R.T. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004, 14:83-90.
21. Lappalainen J., Kranzler H.R., Malison R., Price L.H., Van Dyck C., Rosenheck R.A., Cramer J., Southwick S., Charney D., Krystal J., Gelernter J. A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States. Archives of General Psychiatry 2002, 59:825-831.
22. Lawford B.R., Young R.M., Swagell C.D., Barnes M., Burton S.C., Ward W.K., Heslop K.R., Shadforth S., van Daal A., Morris C.P. The C/C genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia. Schizophrenia Research 2005, 73:31-37.
23. Lerman C., Jepson C., Wileyto E.P., Epstein L.H., Rukstalis M., Patterson F., Kaufmann V., Restine S., Hawk L., Niaura R., Berrettini W. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 2006, 31:231-242.
24. Munafo M.R., Timpson N.J., David S.P., Ebrahim S., Lawlor D.A. Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data. Nicotine & Tobacco Research 2009, 11:64-76.
25. Neville M.J., Johnstone E.C., Walton R.T. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Human Mutation 2004, 23:540-545.
26. Noble E.P. Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. European Psychiatry 2000, 15:79-89.
27. Noble E.P. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. American Journal of Medical Genetics Part B 2003, 116B:103-125.
28. Perkins K.A., Lerman C., Coddington S., Jetton C., Karelitz J.L., Wilson A., Jennings J.R., Ferrell R., Bergen A.W., Benowitz N.L. Gene and gene by sex associations with initial sensitivity to nicotine in nonsmokers. Behavioural Pharmacology 2008, 19:630-640.
29. Perkins K.A., Lerman C., Grottenthaler A., Ciccocioppo M.M., Milanak M., Conklin C.A., Bergen A.W., Benowitz N.L. Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behavioural Pharmacology 2008, 19:641-649.
30. Stapleton J.A., Sutherland G., O'Gara C., Spirling L.I., Ball D. Association between DRD2/ANKK1 Taq1A genotypes, depression and smoking cessation with nicotine replacement therapy. Pharmacogenetics and Genomics 2011, 21:447-453.
31. Styn M.A., Nukui T., Romkes M., Perkins K., Land S.R., Weissfeld J.L. The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in a cohort of participants 1 year after enrollment in a lung cancer screening study. American Journal of Medical Genetics Part B 2009, 150B:254-261.
32. Vandenbergh D.J., O'Connor R.J., Grant M.D., Jefferson A.L., Vogler G.P., Strasser A.A., Kozlowski L.T. Dopamine receptor genes (DRD2, DRD3 and DRD4) and gene-gene interactions associated with smoking-related behaviors. Addiction Biology 2007, 12:106-116.
33. Vink J.M., Willemsen G., Boomsma D.I. Heritability of smoking initiation and nicotine dependence. Behavior Genetics 2005, 35:397-406.
34. Voisey J., Swagell C.D., Hughes I.P., Morris C.P., van Daal A., Noble E.P., Kann B., Heslop K.A., Young R.M., Lawford B.R. The DRD2 gene 957C>T polymorphism is associated with posttraumatic stress disorder in war veterans. Depression and Anxiety 2009, 26:28-33.
35. Wang Z., Ray R., Faith M., Tang K., Wileyto E.P., Detre J.A., Lerman C. Nicotine abstinence-induced cerebral blood flow changes by genotype. Neuroscience Letters 2008, 438:275-280.
36. Wernicke C., Reese J., Kraschewski A., Winterer G., Rommelspacher H., Gallinat J. Distinct haplogenotypes of the dopamine D2 receptor gene are associated with non-smoking behaviour and daily cigarette consumption. Pharmacopsychiatry 2009, 42:41-50.
37. Yoshida K., Hamajima N., Kozaki K., Saito H., Maeno K., Sugiura T., Ookuma K., Takahashi T. Association between the dopamine D2 receptor A2/A2 genotype and smoking behavior in the Japanese. Cancer Epidemiology, Biomarkers & Prevention 2001, 10:403-405.